2020
Czech and Slovak Diamond-Blackfan Anemia (DBA) Registry update: Clinical data and novel causative genetic lesions
VOLEJNIKOVA, Jana, Petr VOJTA, Helena URBANKOVA, Renata MOJZIKOVA, Monika HORVATHOVA et. al.Základní údaje
Originální název
Czech and Slovak Diamond-Blackfan Anemia (DBA) Registry update: Clinical data and novel causative genetic lesions
Autoři
VOLEJNIKOVA, Jana (203 Česká republika), Petr VOJTA (203 Česká republika), Helena URBANKOVA (203 Česká republika), Renata MOJZIKOVA (203 Česká republika), Monika HORVATHOVA (203 Česká republika), Ivana HOCHOVA (203 Česká republika), Jaroslav CERMAK (203 Česká republika), Jan BLATNÝ (203 Česká republika, domácí), Martina SUKOVA (203 Česká republika), Eva BUBANSKA (703 Slovensko), Jaroslava FEKETEOVA (703 Slovensko), Daniela PROCHAZKOVA (203 Česká republika), Julia HORAKOVA (703 Slovensko), Marian HAJDUCH (203 Česká republika) a Dagmar POSPISILOVA (203 Česká republika, garant)
Vydání
Blood Cells, Molecules and Diseases, Orlando, Florida, Academic Press, 2020, 1079-9796
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30205 Hematology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.039
Kód RIV
RIV/00216224:14110/20:00115428
Organizační jednotka
Lékařská fakulta
UT WoS
000510852000001
Klíčová slova anglicky
Cancer; Diamond-Blackfan anemia (DBA); Mutations; Registry; Ribosomal proteins (RP)
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 13. 7. 2020 15:11, Mgr. Tereza Miškechová
Anotace
V originále
Diamond-Blackfan anemia (DBA) is a rare congenital erythroid aplasia, underlied by haploinsufficient mutations in genes coding for ribosomal proteins (RP) in approximately 70% of cases. DBA is frequently associated with somatic malformations, endocrine dysfunction and with an increased predisposition to cancer. Here we present clinical and genetic characteristics of 62 patients from 52 families enrolled in the Czech and Slovak DBA Registry. Whole exome sequencing (WES) and array comparative genomic hybridization (aCGH) were employed to identify causative mutations in newly diagnosed patients and in cases with previously unrecognized molecular pathology. RP mutation detection rate was 81% (50/62 patients). This included 8 novel point mutations and 4 large deletions encompassing some of the RP genes. Malignant or predisposing condition developed in 8/62 patients (13%): myelodysplastic syndrome in 3 patients; breast cancer in 2 patients; colorectal cancer plus ocular tumor, diffuse large B-cell lymphoma and multiple myeloma each in one case. These patients exclusively harbored RPL5, RPL11 or RPS19 mutations. Array CGH is beneficial for detection of novel mutations in DBA due to its capacity to detect larger chromosomal aberrations. Despite the importance of genotype-phenotype correlation in DBA, phenotypic differences among family members harboring an identical mutation were observed.